Last updated: 2026-09-16 09:45:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Schrodinger, Inc. (SDGR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $22.86, with a market capitalisation of $1.55B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $10.95 to $23.71. This page covers its latest market performance, valuation, price trends and company information.
$1.55B | |
$23.07 | |
$117.00 | |
$10.95 | |
$23.25 | |
4.62K | |
1.21M | |
-- | |
$23.71 | |
$10.95 | |
-- | |
-- |
Schrodinger, Inc. (SDGR) is trading at $22.86 in pre-market trading as of 2026-09-16 09:32:00, down 1.68% ($0.39) from the previous close of $23.25
Pre-market trading shows how investors are pricing SDGR before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Schrodinger, Inc. (SDGR) moved from $20.09 to $22.86, representing a gain of 13.78% ($2.77).
The stock traded between $18.63 and $23.71 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.35 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 93.3%
SDGR is currently trading at $22.86, placing it 93.3% of the way from its 52-week low of $10.95 to its 52-week high of $23.71. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 850 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Schrodinger, Inc. (SDGR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.